IGI Inc (IG)

[SmurfVA]

IG - I hope am not too late before this takes off..Reminder Set

[SmurfVA]

IG I need to pick some IG's soon here..ugh!

[SmurfVA]

Stick to what you know for sure with your DD (IPCI solid). Why don't you just split it half/half? Both looks great IMO. Keep both!

[BiotechInvestor90210]

The only reason I'm hesitant about pouring in cash into this company is because the other generic companies I'm in are rising up pretty fast. Can't decide if I want more of those or a soon to be profitable IG. Decisions decisions.

[SmurfVA]

IG - I believe this week should be good time to enter. A lot of things in pipelines, more ANDA's, expected profit and CC to be expected sometime end of this month (Jan.28,2014) -date not yet confirmed but roughly. Shares of IG are up 53% since its last earnings release Key here: To get first two ANDAs approved (assure us liquidity without dilution down the road)

An approval should be imminent IMO just a matter of time here.

[SmurfVA]

IG - Showing strong bullish 3 day chart pattern, Strong 3 day accumulation which occurs 30% of the time. I would say a typical rally would be around 14.7% for her (0.44 pts). She's definitely above her $2.87 resistance here. IG holding very strong IMO. ON WATCH HERE. T1 $3.26 - Do-able.

[SmurfVA]

Will be finding entry point this week!

[BiotechInvestor90210]

Have you jumped in yet?

[BiotechInvestor90210]

... It's something about that generic life lol

[SmurfVA]

LoL! We sure have something in common?! LOL

[BiotechInvestor90210]

They have a huge pipeline and they're submitting ANDA's at a fast rate. Though the products don't have the same market size as IPCI's drugs, they are consistently growing and will most likely hit a profit next quarter for the first time. I got in at about $2.

[BiotechInvestor90210]

Oh my god... Not you again... Lol!

[SmurfVA]

What's new IG members? Anyone care to pitch IG?

[BioSpecialist]

More good news out today ... Now they have 13 Products awaiting FDA approval .GL

IGI Laboratories, Inc. Announces Thirteenth ANDA Submission
http://finance.yahoo.com/news/igi-laboratories-inc-announces-thirteenth-123000375.html

[BioSpecialist]

Great results, great management , full pipeline with 12 products awaiting FDA approval everything is fantastic here .GL



Ticker ( IG )

Market Cap : $86 M
Cash : $2.3 M
Price : $2

Shares Out : 43 M .....(31 Million Shares held by Big Investors)
Float : 11 M

IGI's President and Chief Executive Officer, Jason Grenfell-Gardner, stated, "Our team has done a tremendous job this quarter. This quarter marks the fifth consecutive quarter of top line growth. Our net loss is rapidly approaching break even for the first time at IGI in over twenty-two quarters. We have solidified our market position in our first three IGI labeled topical pharmaceutical products, and we have successfully launched our fourth product, econazole nitrate cream 1%, which we acquired earlier this year, during the third quarter of 2013." Mr. Grenfell-Gardner continued, "Our research and development team has now filed four ANDAs in 2013, which brings our total filings pending with the US FDA to twelve. Based on current IMS data, the addressable market for our pipeline of twelve ANDAs, pending approval at the US FDA is estimated at over $300 million. Our team is committed to our plan to file at least six ANDAs in 2013. We believe we are on track to at least double our 2012 total revenue and achieve profitability in 2013."

[lars1551]

I am holding, recommending, and very positive. I believe based on the 10Q they have close to 1.5M cash which should fund operations for at least a year. If they hit their revenue targets predicted cash will not be the issue. Assuming some good news on any of the ANDA's and this stock could really grow. Look at some of the other players in the sector and you can really see the growth potential. This company has the making's of HUGE returns over the next 5 years. IMO

[Bickema]

Anyone still holding IG shares. I am looking at starting a position. With 12 ANDA's filed with FDA it seems some good news my coming down the pipe soon. One thing that worries me is their need for cash through possible dilution. However It appears they are close to becoming profitable. Thoughts?

Regards, Bickema

[BiotechInvestor90210]

Seriously considering to buy.

[lars1551]

What do you guys make of the high volume with no price move. Typically that would be due to dilution, but I can't figure out why they would dilute the stock at this time. Especially after the recent insider buys. Thoughts?

[Wrinkles]

Exc job Bio, IG is over $2 buckaroos...

[BioSpecialist]

Looks like run over $2++ is possible today ..

[BioSpecialist]

IG has very strong shareholder for a reason, this company is very close to profitability and many products (11) awaiting FDA approval another 3 ANDA filings coming before year end menas they will have 14 ANDA´s awaiting FDA approval by year end . IG submit 6 ANDA´s to FDA per Year and they are on track to be a Top 5 Player in the Topical Space within 5 years means Billion Dollar Company soon . So you know why they have strong Shareholders .GL

Data from CNBC:

Buyers 8/23/13 6,168,256 <<<<
Sellers 8/23/13 515,465


Top 6 Shareholder of IG :

Life Sciences opp Fund 16.4 M
Amzak Capital 3.8 M
Gerardi Francis 3.3 M
Morris Stephen 2.8 M
Hager Edward 2.1 M
Visium assets 1.2 M


Insider buying :

Aug 6, 2013 HEMRIC MICHAEL B.Director 11,902 Direct Purchase at $1.45 per share. 17,257
Aug 5, 2013 HEMRIC MICHAEL B.Director 4,000 Direct Purchase at $1.48 per share. 5,920
Aug 2, 2013 HEMRIC MICHAEL B.Director 10,000 Direct Purchase at $1.48 per share. 14,800
Jul 30, 2013 HEMRIC MICHAEL B.Director 4,508 Direct Purchase at $1.48 per share. 6,671
Jul 26, 2013 HEMRIC MICHAEL B.Director 19,590 Direct Purchase at $1.49 per share. 29,189
May 24, 2013 GRENFELL-GARDNER JASONOfficer 3,500 Direct Purchase at $1.55 per share. 5,425
Mar 13, 2013 ERONY JOYCEDirector 5,000 Direct Purchase at $1.33 per share. 6,650
Mar 13, 2013 GALE JAMES CDirector 10,000 Direct Purchase at $1.33 per share. 13,300
Mar 12, 2013 ERONY JOYCEDirector 12,500 Direct Purchase at $1.30 per share. 16,249
Mar 12, 2013 HEMRIC MICHAEL B.Director 3,000 Direct Purchase at $1.34 per share. 4,020
Mar 11, 2013 HEMRIC MICHAEL B.Director 3,468 Direct Purchase at $1.18 - $1.21 per share. 4,1442
Mar 8, 2013 HEMRIC MICHAEL B.Director 1,532 Direct Purchase at $1.18 per share. 1,807
Mar 7, 2013 HEMRIC MICHAEL B.Director 7,639 Direct Purchase at $1.15 per share. 8,784

[BioSpecialist]

Load up guys before she breaks the $2 ...

[BioSpecialist]

Only a few shares available below $2a close above $2 would be very bullish for IG

[bigwup]

Been in since $1.00 pps large.

[BioSpecialist]

strong buy before its too late guys

[BioSpecialist]

Load up before the stock gets discovered guys ..A super low float here

[BioSpecialist]

$2++ around the corner on upcoming news like Product launch and FDA approvals..

[BioSpecialist]

11x Products awaiting FDA approval // 3x already launched and another one will be launched in this Quarter .

Upcoming Milestones 2013 includes :

1) US Market launch of fourth Product Econazole this Quarter
2) 2-3 FDA approvals expected before year end
3) Another 3 ANDA filings in 2H
4) Achieve Profitability in 2013

[BioSpecialist]

IG-DD // Undiscovered Gem with Monster Upside Potential !!!


Ticker ( NYSE: IG )

Market Cap : $75 M
Cash : $2.3 M
Price : $1.70

Shares Out : 43 M .....(31 Million Shares held by Big Investors)
Float : 11 M

Summary :

1) Laughable Market Cap of $75 M
2) Cash for 12 Months ....... Profitability before Year End
3) 3x Products launched in USA since December 2012
4) Fourth Product will enter the Market in this Quarter
5) 11x Products under review by FDA many of these will get FDA approval within 12 Months
6) Another 3x ANDA filings coming before year end
7) 72% of all Shares Outstanding held by Insiders & Institutions and still buying more
8) Small Float of only ~11 Million Shares

I think targets of $8-12 within 1-2 years is more realistic than Roth Capitals $3.50 .


Massive buying by Institutions
http://data.cnbc.com/quotes/IG/tab/8


and buying by Management
http://www.secform4.com/insider-trading/352998.htm


IGI’s President and Chief Executive Officer, Jason Grenfell-Gardner, stated, “I am extremely pleased with the progress we have made to obtain IGI’s current market position in our first three IGI labeled topical pharmaceutical products. We are ready to launch our fourth product, econazole nitrate cream 1%, which we acquired earlier this year, during the third quarter of 2013 pending final FDA approval of our site transfer. We have expanded our IGI label customer base for our existing product lines, and we continue to explore opportunities to potentially expand our product portfolio. Our formulation and manufacturing contract services revenue continued to grow, and has increased 10% over 2012 year to date.” Mr. Grenfell-Gardner continued, “Our research and development team has filed three ANDAs in 2013, one in January, one in April, and one in July, which brings our total filings pending with the US FDA to 11. Our team is committed to our plan to file at least six ANDAs in 2013. We remain on track for our target to at least double our 2012 total revenue and achieve profitability in 2013
------

[BioSpecialist]

Roth starts IGI Labs at buy
August 7, 2013

Roth Capital Partners has initiated coverage of IGI Laboratories (NYSE MKT:IG) with a “buy” rating and 12-month price target of $3.50, saying the impetus for the rating is “expectations for the company’s internal proprietary generic pipeline to come to fruition and drive sustainable earnings profitability.”

Analyst Scott Henry writes that IGI Labs has 11 ANDAs at the FDA, and “we expect approvals starting in late 2013/early 2014. We view this pipeline as the engine for sustainable profitability in 2014-plus.”

In addition, he said IGI is currently launching two new products – Synalar and econazole nitrate – that could have combined annual peak revenue potential approaching $10-million. These compounds could take the company to earnings breakeven, he added.

“We believe that topicals are among the most attractive segments for an emerging generics company, with higher barriers to entry and better pricing,” he said. “We believe that this further makes IGI Labs a target for industry consolidation.”

[fatcat2]

At least one ANDAs will be approved this year by the FDA. You should listen to CC 1st Quarter 2013. That'll keep you up to date.
I'd like to buy more here, but I've not quite figured where's the bottom. IG also increase shares from 50 Million to 60 Million, which I really don't mind.

[illegal_alias]

That's what I am noticing. I've basically taken my eyes off it over the past 2 years except for stock price. Noticed several ANDAs in the works.

[fatcat2]

3-4 years ago, IG was a contract manufacturer. IG is no longer a contract manufacturer. IG is making it and selling it. That's a BIG plus for IG. Good things will becoming for IG, IMO.

[illegal_alias]

Have watched this one for 3-4 years. Still on watch. I'm thinking next bottom will be the low 1.30s to mid-1.20s.

[fatcat2]

I thinking Bottom has been reach today.

[doogdilinger]

Someone bringin' 'er back to life agreed fatcat! Stop by my doogs dugout board if you're into playin' some amazing movin' pos-land plays that perform well with volume pourin' into them k cheers;)

[fatcat2]

This one seems to be another hidden treasure I found today. I have lots of money to unload on stocks. I'll start my buying of this one probably next week. I'm not to crazy buying on Friday's.

[Penny Roger$]

~ Monday! $IG ~ Earnings posted, pending or coming soon! In Charts and Links Below!

~ $IG ~ Earnings expected on Monday *
Want more like this? Search Keyword: MACMONEY >>> http://tinyurl.com/MACMONEY <<<
One or more of many earnings sites has alerted this security has or will be posting earnings on or around the day of this message.








http://stockcharts.com/h-sc/ui?s=IG&p=D&b=3&g=0&id=p88783918276&a=237480049




http://stockcharts.com/h-sc/ui?s=IG&p=W&b=3&g=0&id=p54550695994



~ Google Finance: http://www.google.com/finance?q=IG
~ Google Fin Options: hhttp://www.google.com/finance/option_chain?q=IG#
~ Yahoo! Finance ~ Stats: http://finance.yahoo.com/q/ks?s=IG+Key+Statistics
~ Yahoo! Finance ~ Profile: http://finance.yahoo.com/q/pr?s=IG
Finviz: http://finviz.com/quote.ashx?t=IG
~ BusyStock: http://busystock.com/i.php?s=IG&v=2


<<<<<< http://www.earningswhispers.com/stocks.asp?symbol=IG >>>>>>



http://investorshub.advfn.com/boards/post_prvt.aspx?user=251916

*If the earnings date is in error please ignore error. I do my best.

[bigwup]

IGI Market Perform target 1.50

Grisewood, CFA, Senior Analyst on IGI Laboratories, Inc. Grisewood establishes a Market Perform rating on the stock, with a 12-month target of $1.50

http://www.tripointglobalresearch.com/research/IG/IG_Report_052511.pdf

Sherry Grisewood, CFA

Ms. Grisewood has over 25 years experience in a range of investment banking and research-related activities. In addition to being an independent strategic and financial advisor, she has also served as a Senior Life Sciences Banker at Jesup & Lamont Securities Corp and as Director of Research/Special Situations Analyst for several mid-tier brokerage companies and a independent on-line investment research company. As an independent advisor and consultant, Sherry has completed extensive research due diligence, competitive intelligence, and business evaluation projects for corporate and investment bank clients, as well as successfully negotiated acquisitions and other strategic transactions between private companies and public companies. The primary focus of these activities is advanced technologies in the life sciences and alternative energy.

In addition to research activities, Ms. Grisewood has published daily market commentary for over 10 years and was a regular commentator on Wall Street Journal Radio until 2004. Sherry holds a Bachelor of Science degree (Highest Honors) in Life Science from Ramapo College of New Jersey and achieved the Chartered Financial Analyst designation in 1990 and is a member of the CFA Institute, NY Society of Security Analysts, and an individual member of the European Federation of Biotechnology, the Tissue Engineering and Regenerative Medicine Society International, the Society of Biomaterials and the American Society of Gene Therapy.

[doogdilinger]

No clue added to radar though & will try to squeeze in some due soon cheers

[Mr. Shagala]

I wonder why its been tanking

[doogdilinger]

Nice close yesterday redsox!

[PremierStocks]

IG

15 minute

[PremierStocks]

YEah man,,,these guys have it going on..

[doogdilinger]

Likewise...extremely interesting technological field here ttys!

[doogdilinger]

Nice read thnx for the link redsox! 56 patents!!!


"I like ridin' lightnin' - my posts are solely my opinion"

[PremierStocks]

OP INSTITUTIONAL HOLDERS
Holder Shares % Out Value* Reported
DIMENSIONAL FUND ADVISORS INC 118,634 .80 $249,131 31-Mar-08
VANGUARD GROUP, INC. (THE) 71,700 .48 $150,570 31-Mar-08
NORTHERN TRUST CORPORATION 23,943 .16 $50,280 31-Mar-08
Bank of New York Mellon Corporation 20,482 .14 $43,012 31-Mar-08
Barclays Global Investors UK Holdings Ltd 18,745 .13 $39,364 31-Mar-08
CALPERS (CALIFORNIA-PUBLIC EMPLOYEES RETIREMENT SYSTEM) 17,800 .12 $37,380 31-Mar-08
BEAR STEARNS & COMPANY 885 .01 $1,858 31-Mar-08
UBS AG 783 .01 $1,644 31-Mar-08
DEUTSCHE BANK AKTIENGESELLSCHAFT 169 .00 $354 31-Mar-08

TOP MUTUAL FUND HOLDERS
Holder Shares % Out Value* Reported
VANGUARD EXTENDED MARKET INDEX FUND 71,700 .48 $150,570 31-Mar-08
DFA U.S. MICRO CAP PORTFOLIO 15,100 .10 $25,821 29-Feb-08
DFA U.S. SMALL CAP SERIES 934 .01 $1,597 29-Feb-08

[PremierStocks]

http://finance.yahoo.com/q/rr?s=IG

[PremierStocks]

2008 2007 $ Change % Change
------ ------- -------- --------
Net income (loss) $ 40 $ (410) $ 450 110%
Net income (loss) per share .00 (.03) .03 100%